HER2; p53 co-mutated cancers show increased histone acetylation and are sensitive to neratinib plus trastuzumab deruxtecan

Authors:
Open Access
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • National Institutes of Health (S10 OD027042)
  • National Cancer Institute (U54 CA224083)
  • Department of Defense, Breast Cancer Research Program (BC170330)